Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Licenses Access to New H1N1 Signatures from CDC

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biosearch Technologies today said that it has licensed from the US Centers for Disease Control and Prevention the new "pdm" H1N1 signatures.

According to Biosearch, the new pdm panel has been optimized for enhanced sensitivity and specificity for H1N1 specimens. The new signatures qualitatively detect currently circulating Novel 2009 H1N1 and offer improved performance over the probe and primer sequences previously published on the World Health Organization’s website, the Novato, Calif.-based firm added.

"As licensors of CDC influenza signatures and as the inventors of BHQ (Black Hole Quencher) technology, Biosearch will provide access to 5’-Nuclease BHQ probes that meet CDC design and manufacturing specifications for PDM Novel 2009 H1N1 testing labs around the world," Marc Beal, director of corporate development at Biosearch, said in a statement.

Terms of the license were not disclosed.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.